49 SEX- AND AGE SPECIFIC ASSOCIATION OF AF WITH MORTALITY IN COVID-19 Anti-arrhythmic drugs (class I, III and/or IV) n (%) 85 (1.8) 9 (2.1) 1.25 (0.56-2.34) Anti-arrhythmic drugs (class I, III and/or IV) NA n (%) 1 (0.0) 1 (0.2) Beta blockers n (%) 1,028 (21.8) 136 (32.4) 1.72 (1.38-2.13) Beta blockers NA n (%) 4 (0.1) 0 (0.0) Antihypertensive drugsd n (%) 1,913 (40.6) 204 (48.6) 1.38 (1.13-1.69) Antihypertensive drugsd NA n (%) 4 (0.1) 0 (0.0) Antithromboticse n (%) 1,296 (27.5) 161 (38.3) 1.64 (1.33-2.01) Antithromboticse NA n (%) 4 (0.1) 0 (0.0) Physical examination, biomarkers (at the start of hospital admission) Temperature in °C median (IQR) 37.8 (37.0-38.6) 37.7 (37.0-38.5) 0.99 (0.89-1.10) Temperature in °C NA median (IQR) 808 (17.1) 106 (25.2) C-reactive protein in mg/L median (IQR) 83.00 (40.75-150.00) 112.00 (61.75-182.10) 1.00 (1.00-1.00) C-reactive protein in mg/L NA median (IQR) 566 (12.0) 64 (15.2) White blood cell count x109/L median (IQR) 6.80 (5.00-9.20) 7.10 (5.00-10.50) 1.03 (1.01-1.05) White blood cell count x109/L NA median (IQR) 505 (10.7) 62 (14.8) Characteristics (during hospitalisation) Duration of hospitalisation in days median (IQR) 8 (4-16) 15 (6-30) 1.02 (1.02-1.03) Duration of hospitalisation in days NA median (IQR) 135 (2.9) 13 (3.1) Development of pulmonary embolism n (%) 317 (6.7) 54 (12.9) 2.06 (1.49-2.78) Development of pulmonary embolism NA n (%) 0 (0.0) 0 (0.0) a There were no missing values for the outcome variable. b Age and BMI were divided into three subgroups (depicted by [X], [X’], and [X’’]) using cubic spline functions, because these variables follow a non-linear pattern with the outcome variable, as visualised in the two graphs below the table. c ST-elevation myocardial infarction or non-ST-elevation myocardial infarction. d Aldosterone antagonists, angiotensin II receptor blockers, angiotensin converting enzyme inhibitors, calcium channel blockers, diuretics. e Platelet inhibitors, anticoagulants. AF: atrial fibrillation; AFL: atrial flutter; BMI: body mass index; CI: confidence interval; COPD: chronic obstructive pulmonary disease; IQR: interquartile range; NA: not available. 3
RkJQdWJsaXNoZXIy MTk4NDMw